iTrack™ is the only illuminated, micron-scale microcatheter designed to viscodilate Schlemm’s canal during MIGS with ABiC™. A standout feature of the iTrack™ is its illuminated tip, which allows you to continually monitor its location during canal circumnavigation.

ABiC WITH iTRACK

SCHEDULE A DEMO

Performed as a standalone procedure or as an adjunct to cataract surgery, ABiC is a new MIGS procedure that can comprehensively restore the natural outflow pathway in glaucoma patients.

Introducing a new comprenhensive MIGS

LEARN MORE

Vitreolysis. Redefining Convention.

Virtually every individual will experience the visual shadows caused by vitreous strands and opacities during their lifetime. Vitreolysis provides an effective outpatient-based treatment for floaters and overcomes many of the risks associated with traditional surgery.

LEARN MORE

SLT. Gentle. Effective Repeatable.

A highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, Selective Laser Trabeculoplasty (SLT) stimulates a natural healing response in the eye to manage intraocular pressure.

LEARN MORE

2RT® is a nanosecond laser therapy that stimulates a natural, biological healing response in the eye to treat degenerative retinal disease, including AMD.

For 30 years, Ellex has been at the forefront of ophthalmic innovation, introducing cutting-edge products and technologies for the diagnosis and treatment of eye disease.

Pioneering solutions for eye care since 1985.

For more than 30 years, Ellex has been committed to the fight against blindness. Our vision is to pioneer integrated medical technologies and solutions for the diagnosis and treatment of eye disease.

A Global Outlook.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in medical technologies. Today, more than 30,000 Ellex laser and ultrasound systems are used around the world in the fight against blindness.

1 December 2008

Results of 2008 Annual General Meeting

Adelaide, Australia, 1 December 2008 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, is pleased to announce the results of resolutions put to the 2008 Annual General Meeting.

Resolution 2a: To re-elect Mr Alex Sundich, who retires by rotation as a Director

The instructions given to validly appoint proxies in respect of the resolution were as follows:

In Favour

Against

Abstention

Proxy’s Discretion

13,455,386

4,896,632

75,900

841,675

Result: Carried

Resolution 2b: To elect Mr Giuseppe Canala as a Director

The instructions given to validly appoint proxies in respect of the resolution were as follows:

In Favour

Against

Abstention

Proxy’s Discretion

13,643,856

4,654,622

130,940

840,175

Result: Carried

Resolution 2c: To elect Mr Malcolm Plunkett as a Director

The instructions given to validly appoint proxies in respect of the resolution were as follows:

Favour

Against

Abstention

Proxy’s Discretion

11,855,702

6,442,776

130,940

840,175

Result: Carried

Resolution 3: To elect Mr Ruediger Naumann-Etienne as a Director

The instructions given to validly appoint proxies in respect of the resolution were as follows:

In Favour

Against

Abstention

Proxy’s Discretion

7,122,027

11,197,663

54,240

895,663

Results of a poll taken at the end of the Annual General Meeting:

In Favour

Against

Abstention

8,870,575

12,749,826

64,240

Result: The resolution was not carried as an ordinary resolution.

Resolution 4: To adopt the Remuneration Report as set out in the Directors Report and Annual Report for the year to June 2008

Favour

Against

Abstention

Proxy’s Discretion

15,570,559

2,582,758

276,741

839,535

Result: Carried

The Board of Ellex advises that after the closure of the 2008 Annual General Meeting, Computershare, Ellex’s share registry agents, notified Ellex of an error in Computershare’s proxy vote calculations. Computershare have unreservedly apologised for this error.

The effect of the error is that certain proxies lodged with Computershare were not included in Computershare’s final proxy advice to the Chairman prior to the close of the Annual General Meeting. This resulted in such proxies not being included in the Chairman’s declaration of, and ruling on, proxy votes to members prior to resolutions being put to members at the Annual General Meeting.

After taking legal advice the Board has ruled that it would not be valid or appropriate to alter the Chairman’s proxy vote declarations and rulings made at the Annual General Meeting.

About Ellex

Ellex Medical Lasers Limited (ASX:ELX) designs, manufactures and sells a complete line of lasers and diagnostic ultrasound systems used by ophthalmologists to diagnose and treat eye diseases. With more than 14,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan and Australia, and a network of distribution partners in more than 100 countries. In December 2006 Ellex acquired Innovative Imaging, a leading provider of diagnostic ultrasound devices for ophthalmology, initiating the expansion of its product line beyond lasers. Ellex maintains a strong emphasis on intellectual property and research into new and better treatments to manage and treat the leading causes of blindness.